Skip to content


Xadago (safinamide) is a small molecule pharmaceutical. Safinamide was first approved as Xadago on 2015-02-23. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against amine oxidase [flavin-containing] B. Xadago's patent is valid until 2031-03-21 (FDA).
Trade Name Xadago
Common Name Safinamide
Indication parkinson disease
Drug Class
Get full access now